Harvard Business Review

SEPTEMBER 20, 2011

A vast ideological gap on macro-economic policy divides Washington and much of the nation, but there is almost universal agreement on one solution: innovation. Innovation is now perceived as a panacea for job creation, income generation, economic growth, dollar strength, and the revival of the U.S. as global hegemon.

Innovation 12

Innovation Supply Chain Offshoring Policies 12

Harvard Business Review

MARCH 2, 2012

As global companies focus their strategies on developed and emerging markets, they require substantial cadres of leaders capable of operating effectively anywhere in the world. economy, expands America's global trade, and attracts foreign companies to base operations in the U.S.

Competitive Advantage 12

Competitive Advantage Globalization Development Intellectual Capital 12

Harvard Business Review

SEPTEMBER 11, 2014

Finally, industries in the upper-right quadrant — such as software, pharmaceuticals, and medical equipment — face high uncertainty in both demand and technology. In other words, if you are in a high uncertainty industry, you must excel at innovation…or die. Customers Innovation Technology'

Uncertainty 18

Uncertainty Industry Bottom-up Technology 18

Harvard Business Review

JANUARY 24, 2012

I'll be joined by five CEOs, among them George Halvorson , who heads the health care provider Kaiser Permanente, Vincent Forlenza who runs Becton Dickinson, the pharmaceutical company, and Tim Brown , the CEO of IDEO, the design and innovation firm. on Friday night.

Meyer 14

Meyer Goleman Emotional Intelligence Pharmaceuticals 14

Harvard Business Review

AUGUST 14, 2018

ineffective innovation strategies. failure to fully embed operations in China. 5 Principles for Innovation in Emerging Markets. Uber’s founder and CEO at the time, Travis Kalanick, took a hands-on role and spent over 20% of his time in China. Uber sold its operation to Didi Chuxing. Related Video.

Competitive Advantage 8

Competitive Advantage Business Model Technology Marketing 8

Harvard Business Review

FEBRUARY 4, 2013

Our research with members of the global C-suite, and with leading sustainability and innovation experts, has identified seven vectors of breakthrough change. Perhaps surprisingly, two leading examples come from pharmaceutical companies. Business would change the rules of the game. Breakthrough Science. Breakthrough Institutions.

EPS 8

EPS Innovation CEO Pharmaceuticals 8

Harvard Business Review

NOVEMBER 28, 2017

Imagine you’re the CEO of a casual dining chain. Doing so entails operating more efficiently or innovating to create products that consumers value more. Anyone who owns or operates a business is well acquainted with the risks, sacrifices, and competitive pressures involved. Paul Garbett for HBR.

Company 8

Company Short-term Long-term Price 8

Harvard Business Review

JUNE 20, 2017

For organizations seeking to become more adaptive and innovative, culture change is often the most challenging part of the transformation. Innovation demands new behaviors from leaders and employees that are often antithetical to corporate cultures, which are historically focused on operational excellence and efficiency.

Company 14

Company Agility Innovation Learning-by-Doing 14

Harvard Business Review

JANUARY 8, 2013

Breaking down functional silos is key to everything from encouraging communication to building valuable connections to sparking innovation. arm of pharmaceuticals manufacturer Boehringer Ingelheim (BIPI). Among the first 100 participants: BIPI's CEO, who was matched with a young member of one of the brand marketing teams. "A

Company 8

Company Pharmaceuticals Health Care Participative 8

Harvard Business Review

MAY 28, 2015

Instead, according to new research from the Center for Talent Innovation (CTI), the fundamental issue is the health care industry’s failure to develop a nuanced understanding of, and commitment to, women as consumers and decision makers. After all, women comprise 88% of the health care workforce — but only 4% of health care CEOs.

Health Care 8

Health Care Industry First-mover Advantage Market Segmentation 8

Harvard Business Review

JUNE 23, 2016

A global pharmaceutical company was about to lose the strategic advantage of several blockbuster drugs coming off patent. Although its readership was at historic highs, the CEO was determined to double its subscription base over the next five years. paul Garbett for HBR. In five years, the revenue shortfall would be significant.

Leadership 8

Leadership Diversity Committee Long-term 8

Harvard Business Review

MAY 16, 2011

Scott McNealy , ex-CEO of Sun Microsystems, tweeted this message last month : "Most over used phrase in business is 'strategic partner.' The Sun-Netscape Alliance was formed when AOL acquired Netscape in 1998 but then sought to spin out the software operations of Netscape. Favorite partnership for me is a purchase order.

Software 14

Software Licensing Long-term Telecommunications 14

Harvard Business Review

OCTOBER 26, 2011

When biotechnology startups like Genentech began to acquire other startups to retain their edge, pharmaceutical incumbents were forced to enter the acquisition melee to remain competitive. Since energy startups operate in an ecosystem dominated by incumbents, they can benefit dramatically from use of incumbent resources.

Energy 10

Energy Finance IPO Biotechnology 10

Harvard Business Review

MAY 10, 2013

The next few product launches were not nearly as successful and Ed Zander , a CEO who came in during the successful period, was unable to come up with any more hits. Such a pattern is well established in the pharmaceutical industry as large established firms partner with smaller biotech firms. Take Motorola, for instance.

Venture Capitalist 8

Venture Capitalist Restructuring Competitive Advantage Short-term 8

Harvard Business Review

MAY 7, 2015

What happened is very well documented: they kept running down the maintenance budget, pushing their operating budget to make their numbers. If you’re Amazon, Disney, some of the pharmaceuticals…the markets support their huge long-term investments because they can see where the investments will lead. Insight Center.

Short-term 8

Short-term Henderson Long-term Metrics 8

Harvard Business Review

DECEMBER 19, 2014

As two of his business units were completing their merger, Peter Noll, chief of the Diagnostics division at the Frankfurt-based Scherr Pharmaceuticals, felt it was time to address a nagging issue: The combined entity had no overarching revenue model. Peter had been appalled by what he found in both units: weak strategic thinking.

Case Study 8

Case Study Price Chemicals Strategy 8